The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

AIMS: The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Stangier, Joachim, Rathgen, Karin, Stähle, Hildegard, Gansser, Dietmar, Roth, Willy
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Science Inc 2007
Konular:
Pharmacokinetics & Pharmacodynamics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000643/
https://ncbi.nlm.nih.gov/pubmed/17506785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02899.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller